nifedipine has been researched along with Esophageal Dysmotility in 8 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ten patients with pulmonary hypertension associated with diffuse systemic sclerosis (1 patient), the CREST syndrome (calcinosis cutis, Reynaud's phenomenon, esophageal dysmotility, sclerodactyl, telangiectasia) (6 patients) and mixed connective tissue disease (3 patients) were studied to assess the effect of oral nifedipine on pulmonary and systemic hemodynamics." | 7.68 | Acute and long-term effects of nifedipine on pulmonary and systemic hemodynamics in patients with pulmonary hypertension associated with diffuse systemic sclerosis, the CREST syndrome and mixed connective tissue disease. ( Alpert, MA; Lambert, CR; Mukerji, B; Mukerji, V; Panayiotou, H; Pressly, TA; Sharp, GC, 1991) |
| " During 12 weeks of prednisone treatment in a dosage of 40 mg daily, her condition markedly deteriorated clinically and hemodynamically as manifested by pulmonary artery pressure (PAP), pulmonary vascular resistance (PVR), cardiac output (CO), mixed venous O2 saturation, and systemic vascular resistance (SVR)." | 5.28 | Nifedipine and prazosin in the management of pulmonary hypertension in CREST syndrome. ( Dresner-Feigin, R; Galun, E; Glikson, M; Pollack, A; Rubinow, A, 1990) |
| "Twelve children were treated with nifedipine, (dysphagia n = 6, gastroesophageal reflux n = 5, swallowing disorder n = 1)." | 3.71 | [Primary esophageal motor disorders in childhood, genuine achalasia excluded]. ( Devouge, E; Gottrand, F; Guimber, D; Lamblin, MD; Michaud, L; Turck, D, 2002) |
| "Ten patients with pulmonary hypertension associated with diffuse systemic sclerosis (1 patient), the CREST syndrome (calcinosis cutis, Reynaud's phenomenon, esophageal dysmotility, sclerodactyl, telangiectasia) (6 patients) and mixed connective tissue disease (3 patients) were studied to assess the effect of oral nifedipine on pulmonary and systemic hemodynamics." | 3.68 | Acute and long-term effects of nifedipine on pulmonary and systemic hemodynamics in patients with pulmonary hypertension associated with diffuse systemic sclerosis, the CREST syndrome and mixed connective tissue disease. ( Alpert, MA; Lambert, CR; Mukerji, B; Mukerji, V; Panayiotou, H; Pressly, TA; Sharp, GC, 1991) |
| "Diffuse esophageal spasm (DES) causes chest pain and/or dysphagia in adults." | 1.39 | Diffuse esophageal spasm in children referred for manometry. ( Cocjin, J; Hyman, PE; Lavenbarg, T; Rosen, JM, 2013) |
| " During 12 weeks of prednisone treatment in a dosage of 40 mg daily, her condition markedly deteriorated clinically and hemodynamically as manifested by pulmonary artery pressure (PAP), pulmonary vascular resistance (PVR), cardiac output (CO), mixed venous O2 saturation, and systemic vascular resistance (SVR)." | 1.28 | Nifedipine and prazosin in the management of pulmonary hypertension in CREST syndrome. ( Dresner-Feigin, R; Galun, E; Glikson, M; Pollack, A; Rubinow, A, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Achem, SR | 1 |
| Calderaro, DC | 1 |
| de Carvalho, MA | 1 |
| Moretzsohn, LD | 1 |
| Rosen, JM | 1 |
| Lavenbarg, T | 1 |
| Cocjin, J | 1 |
| Hyman, PE | 1 |
| Devouge, E | 1 |
| Michaud, L | 1 |
| Lamblin, MD | 1 |
| Guimber, D | 1 |
| Turck, D | 1 |
| Gottrand, F | 1 |
| Kress, S | 1 |
| Benz, C | 1 |
| Riemann, JF | 1 |
| Alpert, MA | 1 |
| Pressly, TA | 1 |
| Mukerji, V | 1 |
| Lambert, CR | 1 |
| Mukerji, B | 1 |
| Panayiotou, H | 1 |
| Sharp, GC | 1 |
| Glikson, M | 1 |
| Pollack, A | 1 |
| Dresner-Feigin, R | 1 |
| Galun, E | 1 |
| Rubinow, A | 1 |
| Baz, RA | 1 |
| Salis, G | 1 |
| Chiocca, JC | 1 |
| Abella, O | 1 |
| Vivante, H | 1 |
| Barcia, J | 1 |
2 reviews available for nifedipine and Esophageal Dysmotility
| Article | Year |
|---|---|
Treatment of non-cardiac chest pain.
Topics: Anti-Ulcer Agents; Botulinum Toxins, Type A; Calcium Channel Blockers; Chest Pain; Diltiazem; Enzyme | 2008 |
[The "nutcracker esophagus." An as yet seldom noticed disease].
Topics: Cholinergic Antagonists; Diagnosis, Differential; Esophageal Motility Disorders; Gastroesophageal Re | 1995 |
6 other studies available for nifedipine and Esophageal Dysmotility
| Article | Year |
|---|---|
Esophageal manometry in 28 systemic sclerosis Brazilian patients: findings and correlations.
Topics: Adult; Antibodies, Antinuclear; Autoantigens; Brazil; Calcium Channel Blockers; DNA Topoisomerases, | 2009 |
Diffuse esophageal spasm in children referred for manometry.
Topics: Adolescent; Age Factors; Calcium Channel Blockers; Chest Pain; Child; Child, Preschool; Cohort Studi | 2013 |
[Primary esophageal motor disorders in childhood, genuine achalasia excluded].
Topics: Adolescent; Age Factors; Child; Child, Preschool; Data Interpretation, Statistical; Deglutition Diso | 2002 |
Acute and long-term effects of nifedipine on pulmonary and systemic hemodynamics in patients with pulmonary hypertension associated with diffuse systemic sclerosis, the CREST syndrome and mixed connective tissue disease.
Topics: Adult; Blood Pressure; Calcinosis; Cardiac Catheterization; Cardiac Output; Dyspnea; Esophageal Moti | 1991 |
Nifedipine and prazosin in the management of pulmonary hypertension in CREST syndrome.
Topics: Adult; Drug Therapy, Combination; Esophageal Motility Disorders; Hemodynamics; Humans; Hypertension, | 1990 |
[Esophageal motility dysfunction and radioisotopes. Its modification with a calcium channel blocker].
Topics: Adult; Aged; Esophageal Motility Disorders; Esophagus; Female; Humans; Male; Manometry; Middle Aged; | 1988 |